News | August 17, 2025
Xspray Pharma licenses patent rights to Handa Therapeutics, secures royalty agreement
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Phase 1 dosing is expected to finish by the end of 2025
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Subscribe To Our Newsletter & Stay Updated
